Health
Weight-Loss Drugs Menace a Sugar Industry in Denial Over Impact
- Traders brushed off the impact of Ozempic-like drugs on sugar
- Still, less-hungry consumers are cutting back on sweet treats
This article is for subscribers only.
In a room filled with more than 800 sugar traders, Sally Lyons Wyatt, an executive at consumer researcher Circana, had an important message to deliver: Ozempic is coming for your industry.
“Does it have the ability to be huge in the future?” she asked during her speech at the New York Sugar Dinner earlier this month. “It does.”